|
Biocon has once again been ranked among the top 10 employers in the global biotech, pharma, and biopharma sectors by the prestigious US-based Science magazine, securing No. 9 spot this year.
This ranking is for both Biocon and Biocon Biologics, since employees of both organizations participated in this survey.
The ranking reflects Biocon’s decade-long recognition as an ‘innovative leader in the industry’. Biocon’s attributes of ‘being socially responsible,’ and ‘a company with ‘loyal employees’ also adds to its attractiveness as a premier biotech employer brand.
Innovation has been a key driver of Biocon's growth, establishing the company as a pioneer in the global biopharmaceuticals industry. Since debuting on the prestigious Science top employers list in 2012, Biocon has consistently featured on it, reflecting its ongoing commitment to excellence and innovation.
Kiran Mazumdar Shaw, chairperson, Biocon Group said: “We have always been R&D led, fostering a culture of ideation, experimentation, and collaboration, keeping patients at the core of its business, which has led it to be placed amongst the ‘Top 10 global employers’ several years in a row by Science magazine. These attributes are appreciated by our people, who are united by the shared purpose of making affordable, high-quality medicines accessible and available to those in need, worldwide.”
This year’s ranking is based on findings from a comprehensive web-based survey of ~6,400 respondents, of whom 65% were from North America, 19% from Europe, and 11% from the Asia/Pacific Rim. About 95% of the respondents worked in biotechnology, biopharmaceutical, and pharmaceutical companies. Employees from both Biocon and Biocon Biologics participated in this survey.
In the top ten ranking, the top honours went to Insmed followed by Regeneron, Incyte, Vertex Pharmaceuticals, Syngenta Group, Spark Therapeutics, Alnylam Pharmaceuticals. Roche excluding Genetech and Biocon which got the ninth place. Genentech stood tenth.
The companies which bagged the positions from 11 to 20 were Abbott, Moderna, Novo Nordisk, GSK, Dr. Reddy’s Laboratories, Eli Lilly and Company, Merck KGaA, Darmstadt, Germany, Boehringer Ingelheim, Merck & Co. and AbbVie.
|